<nqfu class="gzwgpvp"></nqfu>

z6尊龙时凯

Be the most trusted biotech company

2024-07-11

Publication in Journal of Translational Medicine Highlighting Henlius' Dual HER2 Blockade Therapy Mechanism of Action
2024-07-10

Advances in HER2+ GC: Dual HER2 Blockade Therapy Presented on MED and ESMO GI
2024-07-04

Indonesian BPOM and KGbio Visit Henlius: Deepening Cooperation for Mutual Success
2024-07-02

Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC
2024-06-28

Henlius Announces Successful Completion of Phase 1 Clinical Study of Daratumumab HLX15
2024-06-26

Henlius Shines at World ADC Asia 2024, Showcasing Its Innovative R&D Accomplishments in ADC Area
2024-06-21

IMF Chief Economist Visits Henlius: Witnessing China's Economic Vitality and Biopharmaceutical Innovation
2024-06-19

Results from the Preclinical Study of HLX99, an Innovative Neurodegenerative Diseases Therapeutic of Henlius Released at ENCALS Meeting 2024
2024-06-18

Henlius to Make Its Debut at the World ADC Asia 2024

1
2
3
4
5
6
7
...
10